Optimizing the development of antipsychotic drugs

LDR			01155nam a2200337 a 4500
001			003252628
003			MiAaHDL
005			20220528000000.0
006			m d
007			cr bn ---auaua
008			980414s1997 enka b 001 0 eng c
010	⊔	⊔	‡a97003041
015	⊔	⊔	‡aGB97-53302
020	⊔	⊔	‡a0471970115 ‡q(alk. paper)
035	⊔	⊔	‡a(MiU)990032526280106381
035	⊔	⊔	‡asdr-miu.990032526280106381
035	⊔	⊔	‡z(MiU)MIU01000000000000003252628-goog
035	⊔	⊔	‡a(OCoLC)36510640
035	⊔	⊔	‡z(MiU)Aleph003252628
040	⊔	⊔	‡aDNLM/DLC ‡cDLC ‡dNLM ‡dUKM ‡dC#P ‡dEYM
050	0	0	‡aRM333.5 ‡b.O68 1997
060	1	0	‡aQV 77.9 ‡bO63 1997
060	0	0	‡a1998 D-365
082	0	0	‡a615/.788 ‡221
245	0	0	‡aOptimizing the development of antipsychotic drugs / ‡cJohn J. Sramek ... [et al.].
260	⊔	⊔	‡aChichester ; ‡aNew York : ‡bJohn Wiley & Sons, ‡cc1997.
300	⊔	⊔	‡ax, 204 p. : ‡bill. ; ‡c24 cm.
504	⊔	⊔	‡aIncludes bibliographical references and index.
538	⊔	⊔	‡aMode of access: Internet.
650	2	2	‡aClinical Trials.
650	1	2	‡aAntipsychotic Agents ‡xpharmacology.
650	⊔	0	‡aAntipsychotic drugs ‡xDesign.
650	⊔	0	‡aAntipsychotic drugs ‡xTesting.
700	1	⊔	‡aSramek, John J.
899	⊔	⊔	‡a39015041768501
CID	⊔	⊔	‡a003252628
DAT	0	⊔	‡a19980414000000.0 ‡b20220528000000.0
DAT	1	⊔	‡a20220530201409.0 ‡b2024-02-28T18:51:16Z
CAT	⊔	⊔	‡aSDR-MIU ‡dALMA ‡lprepare.pl-004-008
FMT	⊔	⊔	‡aBK
HOL	⊔	⊔	‡0sdr-miu.990032526280106381 ‡aMiU ‡bSDR ‡cMIU ‡pmdp.39015041768501 ‡sMIU ‡1990032526280106381
974	⊔	⊔	‡bMIU ‡cMIU ‡d20240228 ‡sgoogle ‡umdp.39015041768501 ‡y1997 ‡ric ‡qbib ‡tnon-US bib date1 >= 1929